Department of Medicine (Cancer Research), West German Cancer Center, University of Duisburg-Essen, Essen, Germany.
Hum Immunol. 2010 May;71(5):489-95. doi: 10.1016/j.humimm.2010.02.015. Epub 2010 Mar 10.
The aim of this study was to determine the prognostic significance of soluble human leukocyte antigen (HLA) class I (sHLA-I) and HLA-G molecules in lung cancer patients. A total of 23 small-cell lung cancer (SCLC) and 114 non-small-cell lung cancer (NSCLC) patients, including 55 adenocarcinoma, 46 squamous cell carcinoma (SCC), and 13 patients with undifferentiated carcinoma, were prospectively enrolled. Levels of sHLA-G and sHLA-I were analyzed by specific enzyme-linked immunosorbent assay. Median levels of sHLA-G and sHLA-I were significantly increased in patients compared with controls (34 ng/ml [3.6-160] vs 14 ng/ml [0-98], p < 0.0001; 2580 ng/ml [749-5770] vs 1370 ng/ml [274-2670], p < 0.0001, respectively). Regarding the different subgroups, patients with NSCLC or SCLC showed increased sHLA-I levels, whereas sHLA-G was exclusively elevated in NSCLC, especially in patients with SCC. Patients with sHLA-I<2800 ng/ml (p = 0.008) or sHLA-G<40 ng/ml (p = 0.073) showed prolonged overall survival (OS). Using these cut-offs in patients with SCC, a pronounced prognostic significance for sHLA-G (p = 0.003) and sHLA-I (p = 0.004) was observed for the prediction of OS. Here, multivariate analysis confirmed sHLA-G and sHLA-I in addition to disease stage as independent prognostic factors. The prognostic power was further enhanced by combining the two factors and comparing the OS of patients with low sHLA-I and low sHLA-G against the remaining ones. In conclusion, plasma levels of sHLA-G and sHLA-I are potent predictors for OS in lung cancer patients.
本研究旨在确定可溶性人类白细胞抗原（HLA）I 类（sHLA-I）和 HLA-G 分子在肺癌患者中的预后意义。前瞻性纳入了 23 例小细胞肺癌（SCLC）和 114 例非小细胞肺癌（NSCLC）患者，包括 55 例腺癌、46 例鳞状细胞癌（SCC）和 13 例未分化癌患者。通过特异性酶联免疫吸附试验分析 sHLA-G 和 sHLA-I 的水平。与对照组相比，患者的 sHLA-G 和 sHLA-I 中位数水平明显升高（34ng/ml[3.6-160]比 14ng/ml[0-98]，p<0.0001；2580ng/ml[749-5770]比 1370ng/ml[274-2670]，p<0.0001）。关于不同亚组，NSCLC 或 SCLC 患者的 sHLA-I 水平升高，而 sHLA-G 仅在 NSCLC 中升高，尤其是在 SCC 患者中。sHLA-I<2800ng/ml（p=0.008）或 sHLA-G<40ng/ml（p=0.073）的患者总生存期（OS）延长。在 SCC 患者中使用这些截止值，sHLA-G（p=0.003）和 sHLA-I（p=0.004）对 OS 的预测具有显著的预后意义。在这里，多变量分析证实 sHLA-G 和 sHLA-I 以及疾病分期是独立的预后因素。将两个因素结合起来，并比较低 sHLA-I 和低 sHLA-G 患者与其余患者的 OS，进一步增强了预后能力。总之，血浆 sHLA-G 和 sHLA-I 水平是肺癌患者 OS 的有力预测指标。
